Modified antibody compositions, methods of making and using thereof
First Claim
1. A method of manufacturing an activatable antibody, the method comprising:
- (a) culturing a cell comprising a nucleic acid construct that encodes the activatable antibody under conditions that lead to expression of the activatable antibody, wherein the activatable antibody comprises a masking moiety (MM) comprising an amino acid sequence selected from the group consisting of SEQ ID NO;
1, 218-220, 236-265 and 266, a first peptide linker (LP1), a cleavable moiety (CM), a second peptide linker (LP2), and an antibody or an antigen binding fragment thereof (AB) that specifically binds Epidermal Growth Factor Receptor (EGFR),(i) wherein;
the MM has an equilibrium dissociation constant for binding to the AB which is greater than the equilibrium dissociation constant of the AB for binding to EGFR;
(ii) wherein the CM is a polypeptide that functions as a substrate for a protease selected from the group consisting of urokinase type plasminogen activator (uPA), legumain and matriptase (MT-SP1), and wherein the protease cleaves the CM in the activatable antibody when the activatable antibody is exposed to the protease;
(iii) wherein the AB has an equilibrium dissociation constant of at most 100 nM for binding to EGFR;
(iv) wherein each of LP1 and LP2 is a peptide, and wherein the two LPs need not be identical to each other;
(v) wherein the activatable antibody in an uncleaved state has the structural arrangement from N-terminus to C-terminus as follows;
MM-LP1-CM-LP2-AB or AB-LP2-CM-LP1-MM;
(vi) wherein the MM of the activatable antibody in an uncleaved state interferes with specific binding of the AB to EGFR and wherein the MM of the activatable antibody in a cleaved state does not interfere or compete with specific binding of the AB to EGFR; and
(vii) wherein the MM of the activatable antibody in an uncleaved state inhibits the binding of the AB to EGFR such that the dissociation constant (Kd) of the AB of the activatable antibody in an uncleaved state towards EGFR is at least 100 times greater than the Kd of the AB of the activatable antibody in a cleaved state towards EGFR;
and(b) recovering the activatable antibody.
2 Assignments
0 Petitions
Accused Products
Abstract
The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
189 Citations
38 Claims
-
1. A method of manufacturing an activatable antibody, the method comprising:
-
(a) culturing a cell comprising a nucleic acid construct that encodes the activatable antibody under conditions that lead to expression of the activatable antibody, wherein the activatable antibody comprises a masking moiety (MM) comprising an amino acid sequence selected from the group consisting of SEQ ID NO;
1, 218-220, 236-265 and 266, a first peptide linker (LP1), a cleavable moiety (CM), a second peptide linker (LP2), and an antibody or an antigen binding fragment thereof (AB) that specifically binds Epidermal Growth Factor Receptor (EGFR),(i) wherein; the MM has an equilibrium dissociation constant for binding to the AB which is greater than the equilibrium dissociation constant of the AB for binding to EGFR; (ii) wherein the CM is a polypeptide that functions as a substrate for a protease selected from the group consisting of urokinase type plasminogen activator (uPA), legumain and matriptase (MT-SP1), and wherein the protease cleaves the CM in the activatable antibody when the activatable antibody is exposed to the protease; (iii) wherein the AB has an equilibrium dissociation constant of at most 100 nM for binding to EGFR; (iv) wherein each of LP1 and LP2 is a peptide, and wherein the two LPs need not be identical to each other; (v) wherein the activatable antibody in an uncleaved state has the structural arrangement from N-terminus to C-terminus as follows;
MM-LP1-CM-LP2-AB or AB-LP2-CM-LP1-MM;(vi) wherein the MM of the activatable antibody in an uncleaved state interferes with specific binding of the AB to EGFR and wherein the MM of the activatable antibody in a cleaved state does not interfere or compete with specific binding of the AB to EGFR; and (vii) wherein the MM of the activatable antibody in an uncleaved state inhibits the binding of the AB to EGFR such that the dissociation constant (Kd) of the AB of the activatable antibody in an uncleaved state towards EGFR is at least 100 times greater than the Kd of the AB of the activatable antibody in a cleaved state towards EGFR; and (b) recovering the activatable antibody. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 37, 38)
-
-
21. A method of manufacturing an activatable antibody, the method comprising:
-
(a) culturing a cell comprising a nucleic acid construct that encodes the activatable antibody under conditions that lead to expression of the activatable antibody, wherein the activatable antibody comprises a masking moiety (MM) comprising an amino acid sequence selected from the group consisting of SEQ ID NO;
1, 218-220, 236-265 and 266, a first peptide linker (LP1), a cleavable moiety (CM) comprising an amino acid sequence selected from the group consisting of SEQ ID NO;
267-279 and 280, a second peptide linker (LP2), and an antibody or an antigen binding fragment thereof (AB) that specifically binds Epidermal Growth Factor Receptor (EGFR),(i) wherein; the MM has an equilibrium dissociation constant for binding to the AB which is greater than the equilibrium dissociation constant of the AB for binding to EGFR; (ii) wherein the CM is a polypeptide that functions as a substrate for urokinase type plasminogen activator (uPA), and wherein the protease cleaves the CM in the activatable antibody when the activatable antibody is exposed to the protease; (iii) wherein the AB has an equilibrium dissociation constant of at most 100 nM for binding to EGFR; (iv) wherein each of LP1 and LP2 is a peptide, and wherein the two LPs need not be identical to each other; (v) wherein the activatable antibody in an uncleaved state has the structural arrangement from N-terminus to C-terminus as follows;
MM-LP1-CM-LP2-AB or AB-LP2-CM-LP1-MM;(vi) wherein the MM of the activatable antibody in an uncleaved state interferes with specific binding of the AB to EGFR and wherein the MM of the activatable antibody in a cleaved state does not interfere or compete with specific binding of the AB to EGFR; and (vii) wherein the MM of the activatable antibody in an uncleaved state inhibits the binding of the AB to EGFR such that the dissociation constant (Kd) of the AB of the activatable antibody in an uncleaved state towards EGFR is at least 100 times greater than the Kd of the AB of the activatable antibody in a cleaved state towards EGFR; and (b) recovering the activatable antibody. - View Dependent Claims (22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)
-
Specification